Opinion|Videos|October 1, 2024
Overview of BB Use and Outcomes in HFmrEF and HFpEF
Author(s)Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, discusses the data from European Society of Cardiology Congress 2024 on β-blocker use in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, focusing on the study’s objective, design, and methodology as well as key results and takeaways regarding the role of β-blockers in the multimodal management of these HF types.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 on β-blocker (βB) use and outcomes in patients with heart failure with midrange ejection fraction (HFmrEF) and HF with preserved EF (HFpEF).
- What was the objective of this analysis?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. How do βBs play into the multimodal management of HFmrEF and HFpEF?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
2
Patients With Long-Term Conditions Prefer Remote Visits for Routine Care
3
Howard A. “Skip” Burris, III, MD: An Oncology Pioneer Reflects on Patients, Progress, and Purpose
4
Employer Premiums and Deductibles Consume Significant Portion of Income in 19 States
5